Golvatinib tartrate

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameGolvatinib tartrate
Drug Alias Name戈伐替尼golvatinibumgolvatinibE-7050ER-396901-08
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionHepatocyte growth factor receptor inhibitorsVascular endothelial growth factor receptor 2 antagonists
TargetsVascular endothelial growth factor receptor 2Hepatocyte growth factor receptor
Therapy Area/IndicationsSolid tumoursStomach NeoplasmsSquamous Cell Carcinoma of Head and Neck +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesUkraine +[10] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEisai Co LtdQuintiles, Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEisai LtdQuintiles, IncEisai Inc +[4] 
Active IndicationsN/A
Inactive IndicationsSolid tumoursStomach NeoplasmsSquamous Cell Carcinoma of Head and Neck +[5] 

Other Information

ATC CodeN/A
Related LinksKEGG